Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. executive Smital Shah, the Chief Financial and Business Officer, has filed an initial Form 3 as an insider of the company. This filing establishes Shah as a reporting person under SEC rules and, in this instance, does not report any insider transactions.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shah Smital

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/09/2026

3. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Fin. and Bus. Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Mark Meltz, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Lyell Immunopharma (LYEL) Form 3 for Smital Shah show?

The Form 3 identifies Smital Shah, Chief Financial and Business Officer, as an insider of Lyell Immunopharma. It is an initial statement of beneficial ownership and, in this case, does not list any insider buy or sell transactions.

Who is the reporting person in the Lyell Immunopharma (LYEL) Form 3?

The reporting person is Smital Shah, who serves as Chief Financial and Business Officer of Lyell Immunopharma. This role makes Shah a corporate insider, requiring SEC ownership reporting through forms such as Form 3, Form 4, and Form 5 as applicable.

Does the LYEL Form 3 for Smital Shah report any stock transactions?

No transactions are reported in this Form 3. The transaction summary shows zero buys, zero sells, and zero derivative exercises, meaning the filing only serves to establish insider status rather than disclose trading activity in Lyell Immunopharma shares.

What is the purpose of this Lyell Immunopharma (LYEL) Form 3 filing?

This Form 3 serves as an initial statement of beneficial ownership for insider Smital Shah. It formally registers Shah with the SEC as a reporting person at Lyell Immunopharma, enabling future disclosures of share transactions through subsequent ownership reports.

Does the Lyell Immunopharma (LYEL) Form 3 indicate any derivative positions?

The derivative section for this Form 3 is empty, and the derivative transaction count is zero. That means the filing does not list options, warrants, or other derivative securities for Smital Shah, focusing only on establishing insider reporting obligations.